The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Texas MPN Workshop 2022 | An insight into clinical risk factors for progression in MPNs
Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses clinical risk factors for progression in myeloproliferative neoplasms (MPNs). Dr Kuykendall first highlights two key progression events that occur in patients with MPNs: progression from essential thrombocythemia (ET) or polycythemia vera (PV) to myelofibrosis (MF), and progression from ET, PV, or MF to acute leukemia. Dr Kuykendall then highlights cytogenetic factors that play a role in disease progression. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Research fees – Morphosys, GSK
Honoraria – Incyte
